Puma Biotechnology Inc · NASDAQ:PBYI
Puma Biotechnology — Q4 2020 Earnings Presentation
8 slides from Puma Biotechnology's earnings presentation, Feb 25, 2021
Slide 1: Puma Biotechnology Earnings Call Commercial Update
Puma Biotechnology Earnings Call Commercial Update February 25, 2021
Slide 2: Forward-Looking Safe-Harbor Statement
Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could ca
Slide 3: PUMA's Pharmacy and Distributor Network
PUMA’s Pharmacy and Distributor Network Hub Services Specialty Pharmacy Network (SP) Acaria health Accredo CVS ONCO 360 Patients Optum / Biologics Diplomat Sites of Care Specialty Distributor Network (SD) Academic hospitals McKesson Community hospitals ASD/Oncology supply Physician Practices Cardina
Slide 4: ~$50 Million Net NERLYNX Revenue in Q4'20
~$50 Million Net NERLYNX Revenue in Q4’20 Quarterly Net Revenue (in $MM) 61.1 58.7 52.6 53.8 53.5 50.8 50.0 48.6 48.8 49.3 45.6 36.0 20.1 6.1 Copyright 2021 Puma Biotechnology 4
Slide 5: ~3,600 Ex-factory Bottles were Sold in Q4'20
~3,600 Ex-factory Bottles were Sold in Q4’20 Bottles Sold (SP + SD) by Quarter 5,538 4,936 4,935 4,799 4,791 4,696 4,452 4,035 3,728 3,611 3,517 3,585 2,137 675 Includes Commercial SP and SD Copyright 2021 Puma Biotechnology 5
Slide 6: ~38% of Patients in Q4'20 Started at a Reduced Dose
~38% of Patients in Q4’20 Started at a Reduced Dose % of patients starting at reduced dose 37.5% 32.8% 30.4% 30.8% 28.4% 19.0% 12.0% 10.7% 6.3% 6.8% 3.8% 2.5% 2.9% 1.8% Reduced dose defined as fewer than 6 pills per day Copyright 2021 Puma Biotechnology 6
Slide 7: Rest of World Partnerships – Timelines
Rest of World Partnerships – Timelines Region Partner Regulatory / Launch Milestones • March 2019 – Approved in Australia Australia / SE Asia • December 2019 – Approved in Singapore • Q2/Q3 2020 – Approved in Brunei, Malaysia, New Zealand • Q1 2020 – Launched Israel • Q3 2020 – Approved in metastati
Slide 8: Puma Biotechnology Earnings Call Commercial Update
Puma Biotechnology Earnings Call Commercial Update February 25, 2021